AML‐BFM Registry 2017

Author:  Julia Dobke, Last modification: 2024/03/27

AML‐BFM Registry 2017

Registry AML‐BFM 2017


Acute myeloid leukaemia



Problem / Objectives
  • Recording of all AML diseases and their treatment in children and adolescents in the participating centers of all participating countries
  • Recording the genetic, molecular genetic and epigenetic characteristics of AML in children and adolescents
  • Determination of minimal residual disease (MRD) using morphology, immunophenotyping and molecular genetics
  • Determination of the frequency and kinetics of molecular relapse
Therapy / Study arms

The registry is intended to comprehensively record all diseases of children and adolescents with AML and their treatment as well as the cytogenetic, molecular genetic and epigenetic characteristics of AML in children and adolescents. The treatment response to a standardized therapy can also provide important insights into the characterization of AML. Furthermore, the frequency and kinetics of molecular relapse during and after completion of intensive chemotherapy should be recorded, so that the MRD load in peripheral blood should be determined on a monthly basis.

Treatment recomandations

The registry serves exclusively to collect data; no explicit treatment recommendations are made. Patients should be treated according to the recommended standard therapy.

Inclusion Criteria
  • Age from 0 - 17 years
  • de novo AML, myelosarcoma, acute mixed lineage leukemia/biphenotypic leukemia (dominant myeloid according to WHO 2008) or
  • AML as a second malignancy or
  • Transient leukemia and myeloid leukemia with trisomy 21 or
  • Relapsed/refractory AML in children and adolescents or
  • "Special" cases of AML-associated diseases after consultation and approval by the registry center
  • Admission to an accredited pediatric oncology center according to GBA resolution "Pediatric Oncology"
  • Availability of all necessary informed consent forms
Exclusion Criteria
  • Missing informed consent from the patient and/or the legal guardian
Status Start: beginning of 2018, End: until further notice
Principal Investigator Prof. Dr. med. Dirk Reinhardt, Prof. Dr. med. Ursula Creutzig


Prof. Dr. med. Dirk Reinhardt Universitätsklinikum Essen (AöR) Klinik für Kinderheilkunde III Hufelandstraße 55 45147 Essen Telefon +49 (201) 723 3784 Fax +49 (201) 723 5386

Medizinische Beratung

Dr. med. Mareike Rasche Universitätsklinikum Essen Zentrum für Kinder und Jugendmedizin, AML-BFM Studiengruppe Hufelandstr. 55 45147 Essen Telefon 0049 (0)201 723 1051/1052/1053 Fax 0049 (0)201 723 723 5808

Participants Germany, Austria, Tchec Repulic, Switzerland, Slovakia
Link(s) Studienliteratur AML